Evgeniya Trofimova

Dr. Evgeniya Trofimova


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2010 in International Immunopharmacology
Verified
Journal Article
Closed access
NBN.V. Belska
N.V. Belska
AGA.M. Guriev
A.M. Guriev
MDM.G. Danilets
M.G. Danilets
ETEvgeniya Trofimova
Evgeniya Trofimova
EUEvgenya Uchasova
Evgenya Uchasova
YBY.P. Belsky
Y.P. Belsky

8 August 2020 in Cells
Verified
Journal Article
Open access
PDF file
MPMark Borisovich Plotnikov
Mark Borisovich Plotnikov
GCGalina A. Chernysheva
Galina A. Chernysheva
VSVera I. Smolyakova
Vera I. Smolyakova
OAOleg I. Aliev
Oleg I. Aliev
ETEvgeniya Trofimova
Evgeniya Trofimova
Dmitriy AtochinDmitriy Atochin
Dmitriy Atochin
A novel specific inhibitor of c-Jun N-terminal kinase, 11H-indeno[1,2-b]quinoxalin-11-one oxime sodium salt (IQ-1S), has a high affinity to JNK3 compared to JNK1/JNK2. The aim of this work was to study the mechanisms of neuroprotective activity of IQ-1S in the models of reversible focal cerebral ischemia (FCI) in Wistar rats. The animals were administered with an intraperitoneal injection of IQ-1S (5 and 25 mg/kg) or citicoline (500 mg/kg). Administration of IQ-1S exerted a pronounced dose-dependent neuroprotective effect, not inferior to the effects of citicoline. Administration of IQ-1S at doses of 5 and 25 mg/kg reduced the infarct size by 20% and 50%, respectively, 48 h after FCI, whereas administration of citicoline reduced the infarct size by 34%. The administration of IQ-1S was associated with a faster amelioration of neurological status. Control rats showed a 2.0-fold increase in phospho-c-Jun levels in the hippocampus compared to the corresponding values in sham-operated rats 4 h after FCI. Administration of IQ-1S at a dose of 25 mg/kg reduced JNK-dependent phosphorylation of c-Jun by 20%. Our findings suggest that IQ-1S inhibits JNK enzymatic activity in the hippocampus and protects against stroke injury when administered in the therapeutic and prophylactic regimen in the rat model of FCI.

1 February 2021 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
ETEvgeniya Trofimova
Evgeniya Trofimova
MZM. V. Zykova
M. V. Zykova
MDM. G. Danilets
M. G. Danilets
ALA. A. Ligacheva
A. A. Ligacheva
ESE. Yu. Sherstoboev
E. Yu. Sherstoboev
MBM. V. Belousov
M. V. Belousov

20 April 2017 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
ETEvgeniya Trofimova
Evgeniya Trofimova
MZMaria Vladimirovna Zykova
Maria Vladimirovna Zykova
LALigacheva Anastasiya
Ligacheva Anastasiya
ESEugene Sherstoboev
Eugene Sherstoboev
VZV. V. Zhdanov
V. V. Zhdanov
ADA. M. Dygai
A. M. Dygai

1 May 2014 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
GZG. N. Zyuz’kov
G. N. Zyuz’kov
ACA. V. Chaikovskii
A. V. Chaikovskii
LALigacheva Anastasiya
Ligacheva Anastasiya
VZV. V. Zhdanov
V. V. Zhdanov
UEUdut Elena
Udut Elena
ADA. M. Dygai
A. M. Dygai

12 August 2014 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
GZG. N. Zyuz’kov
G. N. Zyuz’kov
MDM. G. Danilets
M. G. Danilets
LALigacheva Anastasiya
Ligacheva Anastasiya
VZV. V. Zhdanov
V. V. Zhdanov
EUE. V. Udut
E. V. Udut
ADA. M. Dygai
A. M. Dygai